Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.

导出 OA

翻译打印收藏纠错

第一作者： Yun Bin,Lee

第一单位： Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.

作者： Yun Bin,Lee ^[1] ; Eun Uk,Jung ^[2] ; Bo Hyun,Kim ^[3] ; Jeong-Hoon,Lee ^[4] ; Hyeki,Cho ^[5] ; Hongkeun,Ahn ^[5] ; Won-Mook,Choi ^[5] ; Young Youn,Cho ^[5] ; Minjong,Lee ^[5] ; Jeong-Ju,Yoo ^[5] ; Yuri,Cho ^[5] ; Dong Hyeon,Lee ^[5] ; Eun Ju,Cho ^[5] ; Su Jong,Yu ^[5] ; Sung Jae,Park ^[2] ; Yoon Jun,Kim ^[5] ; Joong-Won,Park ^[3] ; Youn Jae,Lee ^[2] ; Chang-Min,Kim ^[3] ; Jung-Hwan,Yoon ^[5] ; Chung Yong,Kim ^[5] ; Hyo-Suk,Lee ^[5]

作者单位： Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea. ^[1] Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea. ^[2] Center for Liver Cancer, National Cancer Center, Goyang, Gyeonggi-do, Republic of Korea. ^[3] Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea pindra@empal.com. ^[4] Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. ^[5]